SGLT2 inhibitors are known not only to improve cardiac function and metabolism, but also to promote weight loss by reducing visceral fat depots and to attenuate the obesity-induced inflammatory response and insulin resistance by modulating the activity of M2 macrophages (109, 110). This evidence concerns the gene SLC5A2 and Obesity.